Opinion|Videos|February 13, 2025
Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC
Dr. Kim provides an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC, focusing on the key efficacy outcomes from the phase 3 CROWN trial.
Advertisement
Episodes in this series
This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.
- Dr.Thawani asks Dr. Kim: Can you provide an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC?
- What were the key efficacy outcomes from the phase 3 CROWN trial?
Advertisement
Related to this article
Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.
Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.
At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.
The therapeutic cancer vaccine OSE2101 combined with either docetaxel or nivolumab met the primary end point of 1-year overall survival in the Combi-TED trial.
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.
Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Advertisement
Advertisement
Trending on CancerNetwork
1
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
2
Adjuvant Ribociclib Improves OS at 6 Years in HR+/HER2- Early Breast Cancer
3
Pembrolizumab Plus Chemo Shows Encouraging Activity in NEPC
4
Extended Letrozole Sustains DFS Benefit at 15 Years in HR+ Breast Cancer
5